Aligos 15min Chart Triggers KDJ Death Cross, Bearish Marubozu Signal

The 15-minute chart for Aligos has exhibited a KDJ Death Cross and a Bearish Marubozu pattern at 08/29/2025 13:30. This indicates a shift in momentum towards the downside, with a high likelihood of further decreases in the stock price. Sellers currently dominate the market, and the bearish momentum is expected to persist.

BeOne Medicines AG DRC (NASDAQ: ONC) stock surged by 4.4% following the announcement of positive topline results from a Phase 1/2 study of sonrotoclax in patients with relapsed/refractory mantle cell lymphoma (MCL) [1]. The company reported that the study met its primary endpoint of overall response rate, as assessed by an independent review committee. The trial evaluated sonrotoclax, a next-generation BCL2 inhibitor, in 125 adult patients who had previously been treated with a Bruton’s tyrosine kinase inhibitor and anti-CD20 therapy.

Sonrotoclax demonstrated "clinically meaningful responses" in this heavily pretreated population. The treatment also showed promising results across secondary efficacy endpoints, including complete response rate, duration of response, and progression-free survival. The safety profile was reported as "generally well-tolerated" with "manageable" toxicities.

Lai Wang, PhD, Global Head of R&D at BeOne Medicines, commented, "These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved."

BeOne plans to submit the data to the U.S. Food and Drug Administration and other global regulatory bodies for potential approval. Applications for sonrotoclax are already under review by China’s National Medical Products Administration for potential accelerated approval in R/R MCL and R/R CLL/SLL.

The Phase 3 confirmatory CELESTIAL-RR MCL study is currently underway, with the first patient enrolled earlier this year. The FDA has previously granted sonrotoclax Orphan Drug Designation for treating patients with MCL.

References:
[1] https://www.investing.com/news/stock-market-news/beone-medicines-stock-rises-after-positive-phase-12-results-93CH-4216736